Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10562470 | 0.88 | ALDH1A1 (0.56) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL10561209 | 0.87 | PDE4B (0.56) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL10556383 | 0.87 | HPGD (0.63) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL26659337 | 0.83 | PDE4D (0.66) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL10521349 | 0.83 | HPGD (0.53) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL27780413 | 0.82 | ALDH1A1 (0.51) | PDE4DKDM4EMAPTALDH1A1HPGD | |
| SCHEMBL7479238 | 0.82 | ALDH1A1 (0.57) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL3269737 | 0.82 | PDE4D (0.56) | PDE4DPDE4BKDM4EMAPTALDH1A1 | |
| SCHEMBL6069548 | 0.81 | PDE4D (1.00) | PDE4DPDE4BMAPTALDH1A1NPC1 | |
| SCHEMBL5801416 | 0.80 | PDE4D (0.69) | PDE4DPDE4BKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | claimed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2201002-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
| EP-1248781-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001046172-A1 | PYRAZOLE CYCLIC AMP-SPECIFIC PDE INHIBITORS | ICOS CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | PDE4D 1113/4885PDE4B 1206/4885KDM4E 2286/4885 |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 5/4885PDE4B 2/4885KDM4E 2444/4885 |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | PDE4D 693/4885PDE4B 546/4885KDM4E 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.